Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
World Cup
Elon Musk
Wrestling
Boxing
Donald Trump
Social Media
WWE
Nintendo
Tesla
Baseball
Immigration
Natural Disasters
Published • loading... • Updated

Mediar commences dosing in Phase II trial of MTX-463 for IPF

Summary by Clinical Trials Arena
Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for IPF.The post Mediar commences dosing in Phase II trial of MTX-463 for IPF appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Clinical Trials ArenaClinical Trials Arena

Mediar commences dosing in Phase II trial of MTX-463 for IPF

Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for IPF.The post Mediar commences dosing in Phase II trial of MTX-463 for IPF appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Friday, June 6, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal